- Home
- ELVN
as 12-20-2024 4:00pm EST
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BOULDER |
| Market Cap: | 1.1B | IPO Year: | 2020 |
| Target Price: | $37.80 | AVG Volume (30 days): | 204.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.90 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.90 - $30.03 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Enliven Therapeutics Inc. (ELVN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hohl Benjamin | ELVN | CHIEF FINANCIAL OFFICER | Nov 27 '24 | Sell | $25.08 | 5,250 | $130,688.38 | 1,000 | |
| Hohl Benjamin | ELVN | CHIEF FINANCIAL OFFICER | Oct 28 '24 | Sell | $28.80 | 6,250 | $178,484.63 | 1,000 | |
| Patel Anish | ELVN | CHIEF OPERATING OFFICER | Oct 18 '24 | Sell | $30.00 | 716 | $21,482.51 | 343,311 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Oct 18 '24 | Sell | $30.00 | 847 | $25,412.54 | 1,015,188 | |
| Hohl Benjamin | ELVN | CHIEF FINANCIAL OFFICER | Oct 18 '24 | Sell | $30.00 | 814 | $24,422.44 | 1,000 | |
| Heyman Richard A. | ELVN | Director | Oct 18 '24 | Sell | $30.00 | 1,570 | $47,104.03 | 123,673 | |
| Collins Helen Louise | ELVN | CHIEF MEDICAL OFFICER | Oct 18 '24 | Sell | $30.00 | 816 | $24,482.45 | 0 | |
| Kintz Samuel | ELVN | PRESIDENT AND CEO | Oct 18 '24 | Sell | $30.00 | 924 | $27,722.68 | 1,002,892 | |
| Heyman Richard A. | ELVN | Director | Oct 15 '24 | Sell | $27.67 | 1,270 | $35,143.31 | 123,673 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Oct 8 '24 | Sell | $28.28 | 51,145 | $1,437,585.19 | 1,015,188 |
Latest Enliven Therapeutics Inc. News
ELVN Breaking Stock News: Dive into ELVN Ticker-Specific Updates for Smart Investing
MT Newswires
9 days ago
BTIG Initiates Enliven Therapeutics at Buy With $42 Price Target
PR Newswire
a month ago
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
PR Newswire
a month ago
Enliven Therapeutics to Present at the Jefferies London Healthcare Conference
MT Newswires
2 months ago
JonesTrading Initiates Enliven Therapeutics at Buy With $36 Price Target
Yahoo Finance Video
2 months ago
Why this largely unknown company is one analyst's top biotech pick
Clinical Trials Arena
3 months ago
Enliven Therapeutics’ ELVN-001 shows promise in Phase I CML trial
GlobeNewswire
3 months ago
Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
Zacks
3 months ago
Here's Why Momentum in Enliven Therapeutics, Inc. (ELVN) Should Keep going
Compare ELVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ELVN Enliven Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.